Multi-strain Probiotics (general)
Mixed Lactobacillus + Bifidobacterium blends
Mixed Lactobacillus + Bifidobacterium blends for gut and antibiotic-related conditions
Evidence tier
Strong
Research weight
Citations
9 verified / 9
Classification
Probiotics
❝
What the evidence says. Multiple high-quality RCTs / meta-analyses with consistent effects.
What is Multi-strain Probiotics (general)?
Multi-strain Probiotics (general) (Mixed Lactobacillus + Bifidobacterium blends) is a probiotic strain used for prevents clostridioides difficile-associated diarrhea in adults/children on antibiotics (~60% relative risk reduction; greatest in higher-risk patients). NutriDex grades the human evidence as Strong. Multi-strain Lactobacillus + Bifidobacterium blends have their strongest, most consistent evidence in preventing antibiotic-associated and Clostridioides difficile-associated diarrhea: a 2017 Cochrane review of 39 RCTs (9,955 participants) found probiotics cut C. difficile diarrhea risk by ~60% (RR 0.40), with the benefit concentrated in higher-baseline-risk patients. Specific high-potency 8-strain formulations (the De Simone formulation, formerly VSL#3) have RCT-grade support for inducing remission in mild-to-moderate ulcerative colitis and maintaining remission in pouchitis. Effects are strain- and formulation-specific — not all blends are equally effective, and certainty for IBS from combination products is low. Multiple-strain preparations also appear most effective for preventing necrotizing enterocolitis in preterm infants.
Purported Benefits
✓Prevents Clostridioides difficile-associated diarrhea in adults/children on antibiotics (~60% relative risk reduction; greatest in higher-risk patients)
✓Reduces antibiotic-associated diarrhea; two-strain Lactobacillus+Bifidobacterium mixtures show RR ~0.51
✓Induces and maintains remission in mild-to-moderate ulcerative colitis (8-strain De Simone/VSL#3 formulation)
✓Maintains remission of recurrent/refractory pouchitis (85% vs 6% placebo at 1 year, De Simone formulation)
✓Reduces necrotizing enterocolitis and mortality in preterm infants (multi-strain blends rank most effective)
✓Improves H. pylori eradication rates and reduces eradication-therapy adverse events as adjunct to triple/quadruple therapy
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Prevents C. difficile-associated diarrhea on antibioticsCochrane (39 RCTs) ~60% risk reduction; benefit concentrated in patients with >5% baseline risk. | Strong | ↑ benefit · large | 2 |
| Reduces antibiotic-associated diarrheaMeta-analysis of 19 RCTs; two-strain mixtures RR ~0.51, though not all mixtures effective. | Strong | ↑ benefit · moderate | 1 |
| Induces/maintains remission in UC and pouchitis (8-strain De Simone)RCT-grade support but specific to the high-dose De Simone formulation, not blends generally. | Strong | ↑ benefit · large | 2 |
| Reduces necrotizing enterocolitis and mortality in preterm infantsNetwork meta-analysis (25 trials) ranks multi-strain most effective; heterogeneous products. | Moderate | ↑ benefit · moderate | 1 |
| Improves global IBS symptoms (combination products)Strain/outcome meta-analysis rates combination-probiotic IBS benefit low/very-low certainty. | Preliminary | ↔ mixed · small | 1 |
Dosing & Compounds
Typical Dose
For AAD/CDAD prevention: ~10-50 billion CFU/day, started within 1-2 days of the antibiotic and continued throughout (and a few days after) the course. For ulcerative colitis/pouchitis (De Simone formulation): high dose 3.6 trillion CFU twice daily (induction) or 6 g (~900 billion CFU) once daily (maintenance). Take with or near a meal.
Active Compounds
Safety & Cautions
Generally well tolerated in immunocompetent people; trial adverse-event rates are similar to placebo (mild gas/bloating most common). Caution or avoid in critically ill, immunocompromised, central venous catheter, short-gut, or post-surgical patients — rare bacteremia/sepsis and translocation have been reported, and a probiotic was linked to increased mortality in one severe acute pancreatitis RCT. Product quality and viable CFU vary between brands; effects do not transfer between different strain blends. Educational only — always check with your doctor or pharmacist before combining Multi-strain Probiotics (general) with any medicine.
Key Studies
Cochrane review
Cochrane (Esmaeilinezhad) 2025
✓ PubMed
Updated Cochrane review (search to March 2025): in participants at >5% baseline CDAD risk, probiotics cut CDAD from 11.6% (control) to 3.1% (probiotic) (13 trials, 2454 participants; ~70% relative reduction, NNT=12, moderate certainty).
Systematic review
Cochrane plain-language summary 2025
✓ Full text
In people prescribed antibiotics without a weakened immune system, short-term probiotics may offer a small benefit in preventing CDAD and are likely not harmful; large trials in low-risk populations are still needed.
Systematic review / meta-analysis
Goyal A et al. 2021 (Lancet eClinicalMedicine)
✓ Source
Strain- and outcome-specific meta-analysis of IBS found efficacy for select single strains but low/very-low certainty of benefit for combination (multi-strain) probiotics on global IBS symptoms.
Cochrane systematic review / meta-analysis
Goldenberg JZ et al. 2017 (Cochrane)
✓ Full text
In 39 RCTs (9,955 participants), probiotics reduced C. difficile-associated diarrhea risk by ~60% (RR 0.40, 95% CI 0.30-0.52); benefit was significant only in patients with >5% baseline CDAD risk.
Systematic review / meta-analysis
McFarland LV et al. 2016
✓ Full text
Meta-analysis of 19 RCTs (n=2,730) found some multi-strain probiotic mixtures significantly reduced antibiotic-associated diarrhea, with two-strain mixtures showing RR 0.51 (95% CI 0.38-0.68); not all mixtures were effective.
Systematic review with network meta-analysis
Sniffen JC / McFarland LV et al. 2018
✓ Full text
Network/systematic review showed effects are strain- and product-specific, with several Lactobacillus+Bifidobacterium combinations effective for AAD prevention while others showed no benefit.
Systematic review / network meta-analysis
Chang HY et al. 2017 (PLOS One)
✓ Source
Updated meta-analysis (25 trials, 7,345 preterm infants) found multiple-strain probiotics ranked most effective for preventing necrotizing enterocolitis and reducing all-cause mortality.
Randomized controlled trial
Tursi A et al. 2010
✓ Full text
RCT in mild-to-moderate ulcerative colitis: VSL#3 (3.6 trillion CFU twice daily) plus standard therapy achieved >50% UCDAI improvement in 32.5% vs 10% on placebo at week 6.
Randomized double-blind controlled trial
Mimura T et al. 2004 (Gut)
✓ PubMed
In recurrent/refractory pouchitis, once-daily high-dose VSL#3 maintained remission at 1 year in 85% vs 6% on placebo (p<0.0001); 36 patients randomized.